FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1520294580> ?p ?o ?g. }

• W1520294580 abstract "HomeCirculationVol. 104, No. 15Angiotensin II Type 1 Receptor Blockers and Congestive Heart Failure Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBAngiotensin II Type 1 Receptor Blockers and Congestive Heart Failure Johann W. Auer, MD, Robert Berent, MD and Bernd Eber, MD Johann W. AuerJohann W. Auer 2nd Medical Department, Division of Cardiology and Intensive Care, General Hospital Wels, Grieskirchnerstraße 42, A-4600 Wels, Austria, Search for more papers by this author , Robert BerentRobert Berent 2nd Medical Department, Division of Cardiology and Intensive Care, General Hospital Wels, Grieskirchnerstraße 42, A-4600 Wels, Austria, Search for more papers by this author and Bernd EberBernd Eber 2nd Medical Department, Division of Cardiology and Intensive Care, General Hospital Wels, Grieskirchnerstraße 42, A-4600 Wels, Austria, Search for more papers by this author Originally published9 Oct 2001https://doi.org/10.1161/circ.104.15.e82Circulation. 2001;104:e82To the Editor:We read with great interest the review on angiotensin II type 1 receptor blockers by Michel Burnier.1 He quotes previous investigations, including the results of the Losartan Heart Failure Survival Study (ELITE II)2 and states that “…losartan was not superior to captopril in reducing morbidity and mortality…,” and concludes that “. . .one should be careful before concluding that the class of angiotensin receptor antagonists is less effective than ACE inhibitors in the treatment of congestive heart failure… .” On the basis of the results of ELITE II and the preliminary results of the Valsartan Heart Failure Trial (Val-HeFT),3 we do not agree with this interpretation. Data from several large-scale clinical trials strongly support a benefit of treatment with β-blockers in patients with advanced stages of congestive heart failure.4In ELITE II,2 in the subset of patients taking β-blockers at randomization (22% of the population), total mortality reduction differed significantly between the losartan and captopril groups in favor of the angiotensin-converting enzyme (ACE) inhibitor captopril. In Val-HeFT,3 ≈35% of the patients were taking β-blockers at baseline. Among these patients, the point estimate actually trended toward a negative effect with valsartan.On the basis of the currently available data, one should conclude that, particularly in patients taking β-blockers (which are recommended for all patients with stable NYHA class II and III heart failure due to left ventricular systolic dysfunction without contraindication5), the class of angiotensin receptor antagonists is probably less effective than are ACE inhibitors in the treatment of congestive heart failure.We agree with Burnier that angiotensin II receptor blockers may be considered in heart failure patients developing an ACE inhibitor–induced cough. Additional studies are ongoing, and their results will have to be taken into account to evaluate the definite place of angiotensin II receptor antagonists in heart failure. References 1 Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001; 103: 904–912.CrossrefMedlineGoogle Scholar2 Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355: 1582–1587.CrossrefMedlineGoogle Scholar3 Cohn JN. Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. Presented at the 73rd Scientific Sessions of the American Heart Association, New Orleans, La, November 12–15, 2000.Google Scholar4 MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353: 2001–2007.CrossrefMedlineGoogle Scholar5 Packer M, Cohn JN. Consensus recommendations for the treatment of chronic heart failure. Am J Cardiol. 1999; 83 (2A): 1–35.CrossrefMedlineGoogle ScholarcirculationahaCirculationCirculationCirculation0009-73221524-4539Lippincott Williams & WilkinsResponseBurnier Michel, , MD09102001Dr Auer and colleagues suggest that on the basis of the results of the Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT), one should conclude that the class of angiotensin receptor antagonists is less effective than are angiotensin-converting enzyme (ACE) inhibitors in the treatment of congestive heart failure in patients taking β-blockers. I do not think that the results of these 2 studies allow such a conclusion.In the ELITE II study, the number of patients included in the β-blocker subgroup analysis was small.1 Thus, as stated by Pitt and colleagues,1 “the interaction should be interpreted with caution.” Furthermore, the dose of losartan used in this study was low (50 mg) and certainly insufficient to block the renin-angiotensin system for 24 hours.2 Therefore, one cannot exclude the possibility that a higher dose of losartan would be as effective as an ACE inhibitor, even in patients receiving β-blockers.With regard to the Val-HeFT study,3 several points should be taken into account. First, the results have not yet been published. It is difficult, therefore, to discuss the data in much detail. Second, the goal of Val-HeFT was not to compare the efficacy of an ACE inhibitor with that of an angiotensin II receptor antagonist but rather to evaluate the potential benefits of valsartan administered in addition to an ACE inhibitor. Third, to my knowledge, the randomization was not stratified on the basis of the concurrent use of β-blockers. Thus, there may be potential bias related to the reasons for administering β-blockers. Taken together, the results of Val-HeFT do not provide any solid information regarding the comparative efficacy of ACE inhibitors and angiotensin II receptor antagonists in patients with congestive heart failure who are being treated with β-blockers. It is important to mention, however, that in ACE-intolerant patients, valsartan was remarkably effective, which clearly indicates that heart failure patients can benefit from angiotensin II receptor blockade. With regard to the potential interaction between the use of β-blockers and the effects of angiotensin II receptor antagonists, specific studies should be designed to answer the question. In the meantime, I would not recommend the avoidance of angiotensin II receptor blockers in heart failure patients who are being treated with β-blockers. Previous Back to top Next FiguresReferencesRelatedDetailsCited By LUO J, CHIU R and SHUM-TIM D (2007) Bone marrow stromal cells as ‘universal donor cells' for myocardial regeneration therapy Artificial Cells, Cell Engineering and Therapy, 10.1533/9781845693077.4.333, (333-348), . October 9, 2001Vol 104, Issue 15 Advertisement Article InformationMetrics https://doi.org/10.1161/circ.104.15.e82PMID: 11591633 Originally publishedOctober 9, 2001 PDF download Advertisement" @default.
• W1520294580 created "2016-06-24" @default.
• W1520294580 creator A5049445187 @default.
• W1520294580 creator A5061452623 @default.
• W1520294580 creator A5075114476 @default.
• W1520294580 date "2001-10-09" @default.
• W1520294580 modified "2023-09-30" @default.
• W1520294580 title "Angiotensin II Type 1 Receptor Blockers and Congestive Heart Failure" @default.
• W1520294580 cites W2090136581 @default.
• W1520294580 cites W2100082183 @default.
• W1520294580 cites W52877415 @default.
• W1520294580 doi "https://doi.org/10.1161/circ.104.15.e82" @default.
• W1520294580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11591633" @default.
• W1520294580 hasPublicationYear "2001" @default.
• W1520294580 type Work @default.
• W1520294580 sameAs 1520294580 @default.
• W1520294580 citedByCount "2" @default.
• W1520294580 countsByYear W15202945802017 @default.
• W1520294580 crossrefType "journal-article" @default.
• W1520294580 hasAuthorship W1520294580A5049445187 @default.
• W1520294580 hasAuthorship W1520294580A5061452623 @default.
• W1520294580 hasAuthorship W1520294580A5075114476 @default.
• W1520294580 hasBestOaLocation W15202945801 @default.
• W1520294580 hasConcept C126322002 @default.
• W1520294580 hasConcept C164705383 @default.
• W1520294580 hasConcept C170493617 @default.
• W1520294580 hasConcept C198710026 @default.
• W1520294580 hasConcept C2778198053 @default.
• W1520294580 hasConcept C2908929049 @default.
• W1520294580 hasConcept C2910553456 @default.
• W1520294580 hasConcept C71924100 @default.
• W1520294580 hasConcept C84393581 @default.
• W1520294580 hasConceptScore W1520294580C126322002 @default.
• W1520294580 hasConceptScore W1520294580C164705383 @default.
• W1520294580 hasConceptScore W1520294580C170493617 @default.
• W1520294580 hasConceptScore W1520294580C198710026 @default.
• W1520294580 hasConceptScore W1520294580C2778198053 @default.
• W1520294580 hasConceptScore W1520294580C2908929049 @default.
• W1520294580 hasConceptScore W1520294580C2910553456 @default.
• W1520294580 hasConceptScore W1520294580C71924100 @default.
• W1520294580 hasConceptScore W1520294580C84393581 @default.
• W1520294580 hasIssue "15" @default.
• W1520294580 hasLocation W15202945801 @default.
• W1520294580 hasLocation W15202945802 @default.
• W1520294580 hasOpenAccess W1520294580 @default.
• W1520294580 hasPrimaryLocation W15202945801 @default.
• W1520294580 hasRelatedWork W1491055865 @default.
• W1520294580 hasRelatedWork W2012241433 @default.
• W1520294580 hasRelatedWork W2039995053 @default.
• W1520294580 hasRelatedWork W2051712573 @default.
• W1520294580 hasRelatedWork W2076843464 @default.
• W1520294580 hasRelatedWork W2077083067 @default.
• W1520294580 hasRelatedWork W2314128040 @default.
• W1520294580 hasRelatedWork W2965474825 @default.
• W1520294580 hasRelatedWork W4247718175 @default.
• W1520294580 hasRelatedWork W4315784592 @default.
• W1520294580 hasVolume "104" @default.
• W1520294580 isParatext "false" @default.
• W1520294580 isRetracted "false" @default.
• W1520294580 magId "1520294580" @default.
• W1520294580 workType "article" @default.